Virtual Library
Start Your Search
Y. Fan
Author of
-
+
P3.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 208)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 2
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.01-018 - Icotinib for Control of Leptomeningeal Carcinomatosis in Non-Small Cell Lung Cancer with Sensitive EGFR Mutations (ID 1410)
09:30 - 09:30 | Author(s): Y. Fan
- Abstract
Background:
The incidence rate of leptomeningeal carcinomatosis (LC) has been increased in advanced non-small cell lung cancer (NSCLC) patients, especially with EGFR mutations. The purpose of this study was to evaluate the efficacy of icotinib for the control of LC in NSCLC with sensitive EGFR mutations.
Methods:
Twenty-one NSCLC patients with sensitive EGFR mutations and cytologically proven LC diagnoses between 2011 and 2014 at Zhejiang Cancer Hospital were retrospectively reviewed.
Results:
Ten patients had exon 21 point mutations and eleven patients had exon 19 deletional mutations. Sixteen of 21 patients received standard dose of icotinib (125 mg/day, three times a day) after LC diagnoses. The other five patients had already used icotinib and switched to double dose of icotinib (250 mg/day, three times a day) after LC occurrence. Eight patients received intrathecal chemotherapy, and nine of them were treated with combined whole-brain radiotherapy. Eighteen of 20 patients (90.0%) showed improvement of dizziness and headache. Seventeen of 21 patients (80.9%) had an improved Eastern Cooperative Oncology Group performance status (ECOG PS) score after icotinib treatment. The median overall survival was 10.1 months (95% CI: 8.4–12.0). Univariate analysis showed that the poor ECOG PS score (PS > 2), coexisting parenchymal brain metastasis, and the taken of icotinib were unfavorable prognostic factors for patient survival.The ECOG PS scare was an only independently predictor for survival in the multivariable analysis.
Conclusion:
This study suggested that icotinib had efficacy for the control of LC in NSCLC with sensitive EGFR mutations and was well tolerated. The Further prospective study is warranted.
-
+
P3.01-050 - A Interim Analysis of Randomized Phase III Trial of Nedaplatin or Cisplatin Combined with Docetaxel as First-Line Treatment for Advanced ASQC (ID 1225)
09:30 - 09:30 | Author(s): Y. Fan
- Abstract
Background:
Cisplatin combined with docetaxel is one of the stand treatment in advanced squamous cell carcinoma(ASQC) of the lung. Nedaplatin combined with docetaxel has demonstrated potent activity in ASQC in phase II study. But until now there is no randomized phase III study comparing these 2 chemotherapy regimens. The aim of this study was to evaluate and compare the efficacy and safety between the combination chemotherapy of nedaplatin or cisplatin plus docetaxel in patients with ASQC.
Methods:
This is a multicentre, open-label, randomized, phase III study in China (NCT02088515). Chemo-naive stage IIIB/IV squamous NSCLC with Eastern Cooperative Oncology Group performance status 0/1 were randomized (1:1) to four cycles of nedaplatin (80 mg/m[2]) plus docetaxel(75 mg/m[2]) or cisplatin(75 mg/m[2]) plus docetaxel (75 mg/m[2]) . The primary endpoint was progression-free survival (PFS). Secondary end points were overall survival (OS), overall response rate (ORR), disease control rate (DCR) and quality of life.
Results:
From December 2013 to January 2015, 117 patients were accrued: nedaplatin plus docetaxel (n = 57) and cisplatin plus docetaxel (n = 60). The objective response rates were 27% and 31% and the disease control rate were 78.92 % and 82.67% in nedaplatin and cisplatin groups, respectively. There is no significance difference in nausea / vomiting(21% vs 30%) , diarrhea(3% vs 5%), liver dysfunction(12% vs 15%), neutropenia(60% vs 65%), thrombocytopenia(10% vs 12%), anemia(8% vs 7%) between the 2 arms. The renal dysfunction incidence is higher in the cisplatin group(3% vs 0%). Although there is no 3/4 grade toxicities difference between 2 arms including nausea / vomiting(0% vs 0%) , diarrhea(0% vs 1%), liver dysfunction(0% vs 0%), renal dysfunction(0% vs 0%) , neutropenia(4% vs 3%), thrombocytopenia(0% vs 0%), anemia(0% vs 0%) . This is an interim analysis and we haven't got the data of survival and quality of life.
Conclusion:
There is no ORR difference between the group of nedaplatin plus docetaxel and cisplatin plus docetaxel. But the toxicity of nedaplatin regiment is less toxicities, especially in renal toxicity,as first-line treatment for patients with advanced squamous NSCLC
